Cancer 'chemotherapia specifica' ninety years after Paul Ehrlich

Chemotherapy

Volumn 53, Issue 5, 2007, Pages 309-312

  Shukla, Shyama K ^a,b   Petrucci, Francesco ^c   Caimi, Stefano ^c   Alimonti, Alessandro ^c   Cusumano, Roberto ^d  

^a S EUGENIO HOSPITAL   (Italy)

^b CNR Consiglio Nazionale delle Ricerche   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d Aurelia Hospital   (Italy)

Author keywords

'Chemotherapia specifica'; Cancer therapy; Ehrlich, Paul

Indexed keywords

CIGARETTE SMOKE; GALLIUM 67; TECHNETIUM 99M;

BODY DISTRIBUTION; CANCER CHEMOTHERAPY; CANCER THERAPY; CIGARETTE SMOKING; MASS SPECTROMETRY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SCIENTIST;

DRUG THERAPY; DRUG TOXICITY; HISTORY, 20TH CENTURY; HUMANS; NEOPLASMS; RISK FACTORS;

EID: 34548672111     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000107688     Document Type: Review

References (33)

1. Sörgel F: World Conference on Dosing of Antiinfectives: 'Dosing the Magic Bullets'. Celebrating the 150th Birthday of Paul Ehrlich, the 'Founder of Chemotherapy', September 9-11, 2004, Nürnberg, Germany. Chemotherapy 2004;50:1-5.
2. Sörgel F: The return of Ehrlich's 'Therapia magna sterilisans' and other Ehrlich concepts? Series of papers honoring Paul Ehrlich on the occasion of his 150th birthday. Chemotherapy 2004;50:6-10.
3. Schwartz RS: Paul Ehrlich's magic bullets. N Engl J Med 2004;350:1079-1080.
4. Winau F, Westphal O, Winau R: Paul Ehrlich - in search of the magic bullet. Microbes Infect 2004;6:786-789.
5. Stern F: Paul Ehrlich: the founder of chemotherapy. Angew Chem Int Ed Engl 2004;43:4254-4261.
6. Prull CR: Paul Ehrlich as clinical pathologist. Schweiz Rundsch Med Prax 2004;93:1707-1710.
7. Drews J: Paul Ehrlich: magister mundi. Nat Rev Drug Discov 2004;3:797-801.
8. Brath K: Paul Ehrlich was born 150 years ago. The benefactor of humanity (in German). MMW Fortschr Med 2004;146:65.
9. Shukla SK, Petrucci F, Alimonti A, Cusumano R, Cusumano S, Cristalli M, Atzei G, Cipriani C: 'Chemotherapia specifica' for the cure of bladder cancer. Anticancer Res 2004;24:3561.
10. Ehrlich P: Relations existing between chemical constitution, distribution, parmaceutical action, Leyden-Festschrift 1902; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Histology, Biochemistry and Pathology. London, Pergamon Press, 1956, vol 1, pp 596-618.
11. Ehrlich P: Chemotherapeutische Trypanosomen Studien; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Chemotherapy. London, Pergamon Press, 1960, vol 3, p 81.
12. Shukla SK, Castelli L, Cipriani C, Manni GB: What is good in gallium-67 citrate and how does it increase its tumour affinity? Radioakt Isotope Klin Forsch 1980;14:179-196.
13. Shukla SK, Cipriani C, Argirò G, Baziotis N, Xie H, Sharma HL, Cristalli M, Muller A: Pure radionuclide species in the study of biochemical nature of cancer and in its diagnosis and therapy. J Exp Clin Cancer Res 1992;11(suppl):84.
14. Shukla SK, Frosi AM, Cipriani C, Argirò G, Hermes R, Cristalli M, Boemi S, Schomacker K: 'Chemotherapia specifica' with tumouraffine gallium species in solution; in Einhorn J, Nord CE, Norby SR (eds): Recent Advances in Chemotherapy. Proc 18th Int Congr Chemotherapy, Stockholm, June 27-July 2, 1993. Washington, American Society of Microbiology, 1994, pp 849-850.
15. Ehrlich P, Gonder P: Experimentelle Chemotherapie; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Chemotherapy. London, Pergamon Press, 1960, vol 3, pp 559-582.
16. Müller FH: Tabakmissbrauch und Lungencarcinom. Z Krebsforsch 1939;49:57-85.
17. Bäumler E: Paul Ehrlich. Scientist for Life. New York, Holmes & Meier, 1984, pp 219-220.
18. Ehrlich P: Letter of Paul Ehrlich to C.A. Herter; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Histology, Biochemistry and Pathology. London, Pergamon Press, 1956, vol 1, pp 9-11.
19. Ehrlich P: Address delivered by Paul Ehrlich at the dedication of Georg-Speyer Haus, 6 Sept 1906; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Chemotherapy. London, Pergamon Press, 1960, vol 3, pp 53-63.
20. Ehrlich P, Karrer P: Ueber Arseno-Stibino und Arseno-Bismuto- Verbindungen; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Chemotherapy. London, Pergamon Press, 1960, vol 3, pp 554-558.
21. Ehrlich P, Karrer P: Arseno-Metallverbindungen; in Himmelweit F (ed): The Collected Papers of Paul Ehrlich. Chemotherapy. London, Pergamon Press, 1960, vol 3, pp 587-594.
22. Rosenberg B: Anticancer activity of cis-dich lorodiammineplatinum(II) and some relevant chemistry. Cancer Treat Rep 1979;63:1433-1438.
23. Wientjes MG, Badalament RA, Au JL: Use of pharmacologic data and computer simulations to design an efficacy trial of intravesical mitomycin C therapy for superficial bladder cancer. Cancer Chemother Pharmacol 1993;32:255-262.
24. Au JL, Badalament RA, Wientjes MG, Young DC, Warner JA, Venema PL, Pollifrone DL, Harbrecht JD, Chin JL, Lerner SP, Miles BJ: Methods to improve efficacy of intravesical mitomycin C: results of a randomized phase III trial. J Natl Cancer Inst 2001;93:597-604.
25. Malmstrom PU: Advances in intravesical therapy of urinary bladder cancer. Expert Rev Anticancer Ther 2004;4:1057-1067.
26. Lamm DL, Riggs DR, Traynelis CL, Nseyo UO: Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder. J Urol 1995;153:1444-1450.
27. Tolmachev V, Carlsson J, Lundqvist H: A limiting factor for the progress of radionuclide-based cancer diagnostics and therapy. Availability of suitable radionuclides. Acta Oncol 2004;43:264-275.
28. Rosenberg JE, Carroll PR, Small EJ: Update on chemotherapy for advanced bladder cancer. J Urol 2005;174:14-20.
29. IARC: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 38: Tobacco Smoking. Lyon, IARC Press, 1986.
30. IARC: IARC Monographs on the Evaluation of Carcinogenic Risks to Humans. Vol 83: Tobacco Smoke and Involuntary Smoking. Lyon, IARC Press, 2004.
31. Church DF, Pryor WA: Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985;64:111-126.
32. Kilburn KH: Stop inhaling smoke: prevent coronary heart disease. Arch Environ Health 2003;58:68-73.
33. Forte G, Bocca B, Senofonte O, Petrucci F, Brusa L, Stanzione P, Zannino S, Violante N, Alimonti A, Sancesario G: Trace and major elements in whole blood, serum, cerebrospinal fluid and urine of patients with Parkinson's disease. J Neural Transm 2004;111:1031-1040.